Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Translational Cancer Research"
DOI: 10.21037/tcr-22-2030
Abstract: Background Pemetrexed plus platinum alone is the conventional first-line therapy for locally advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable genetic aberrations. The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could… read more here.
Keywords: plus platinum; patients nonsquamous; cost; first line ... See more keywords